A new cell therapy company takes its vision from four founders, and its skin from George Church

GC Therapeutics, a biotech startup that is writing the recipe book for turning a stem cell into nearly any natural human cell, formally launched Thursday

GC Therapeutics has Church’s initials, a 4-day cell differentiation platform, and $65 million

Renowned Harvard geneticist and serial entrepreneur George Church is at it again, with a venture that has raised $75 million from investors.

“Our technology allows us to discover novel cell-differentiation recipes and make practically any cell type in the body, including those that have not been made before,” said Alex Ng, co-first author with Parastoo Khoshakhlagh

GCTx founders co-authored with other distinguished US and international scientists "A comprehensive library of human transcription factors for cell fate engineering" published in the November 2020 issue of Nature Biotechnology

Harvard Medical School describes how GCTx is tackling COVID-19 utilizing our TFome cell engineering technology

Biogen awarded GCTx Golden Tickets, which provide lab space at Lab Central

CBS 60 Minutes featured our synthetic biology-based cell therapy platform technology

“The people who want to change the world are people who want to keep moving,” said Harvard President Lawrence Bacow during the ceremony

“The teams competing in this year’s President’s Innovation Challenge (PIC) represent the extraordinary talent that exists across the University,” said Harvard President Lawrence Bacow GCTx: Revolutionizing cell therapy by building a cell engineering platform that is 100 times faster and 10 times more efficient, enabling customized therapeutics tailored to target hard-to-cure diseases

Award recognizes TFome platform technology that enables rapid engineering of a broad spectrum of tissue-specific cell types